# Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Study · id `cardio:ct-nct02923115` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02923115](<https://clinicaltrials.gov/study/NCT02923115>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02923115

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 134 participants.

## Technical summary

Registry record NCT02923115. Randomized; double masking; primary purpose treatment. Start 2016-06-23 (actual); primary completion 2019-08-05 (actual). Results posted on 2020-07-30.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 134 participants (enrolled count; ClinicalTrials.gov record NCT02923115, source copy `cardio:ctgov-nct02923115-2023-04-19`, retrieved 2026-10-31)
- Started: 2016-06-23 (actual) (ClinicalTrials.gov record NCT02923115, source copy `cardio:ctgov-nct02923115-2023-04-19`, retrieved 2026-10-31)
- Primary completion: 2019-08-05 (actual) (ClinicalTrials.gov record NCT02923115, source copy `cardio:ctgov-nct02923115-2023-04-19`, retrieved 2026-10-31)
- Completion: 2019-08-05 (actual) (ClinicalTrials.gov record NCT02923115, source copy `cardio:ctgov-nct02923115-2023-04-19`, retrieved 2026-10-31)
- Results first posted: 2020-07-30 (ClinicalTrials.gov record NCT02923115, source copy `cardio:ctgov-nct02923115-2023-04-19`, retrieved 2026-10-31)
- Countries: United States; Austria; Belgium; France; Germany; Italy; Netherlands; Spain (ClinicalTrials.gov record NCT02923115, source copy `cardio:ctgov-nct02923115-2023-04-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02923115-2023-04-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
- Condition: Pulmonary Embolism
- Condition: Thrombotic Disease
- Intervention (Drug): DS-1040b
- Intervention (Drug): Placebo
- Intervention (Drug): Enoxaparin
- Lead sponsor: Daiichi Sankyo
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Enoxaparin (`core:enoxaparin`)
- Registry lists this organization as the lead sponsor: Daiichi Sankyo (`cardio:org-daiichi-sankyo`)

## Provenance

Content hash: 3e884e310fd413828df46f40af6802ef0f8cb2d154c7a476083675631548ff21
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
